Lenalidomide Capsule
Product Images NDC 82293-006

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 82293-006). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novugen Pharma (usa) Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 mg (Label)

Label for Lenalidomide Capsules 10 mg, distributed by Novugen Pharma (USA) LLC. The label indicates 28 capsules per package, with a warning about potential human birth defects. Storage instructions specify 20°C to 25°C with allowable excursions. The product is made in India and includes a barcode and space designated as an unvarnish area measuring 22mm by 30mm.*

FDA Label Image

15 mg (Label)

The label for Lenalidomide Capsules 15 mg includes a warning about potential human birth defects. It contains 21 capsules and advises pharmacists to provide the Medication Guide. Distributed by Novugen Pharma (USA) LLC, Princeton, NJ, the product is made in India. Storage instructions specify controlled room temperature from 20°C to 25°C with permitted excursions. The label also features two barcodes and an unvarnished area for batch and serial number printing.*

FDA Label Image

2.5 mg (Label)

Label for Lenalidomide Capsules 2.5 mg by Novugen Pharma (USA) LLC. The label indicates 28 capsules per container and includes warnings about potential human birth defects. It states the drug is Rx only and made in India. Storage instructions specify 20°C to 25°C with permitted excursions. The label also shows NDC 82293-006-10 and includes barcodes and areas designated for batch and serial number printing.*

FDA Label Image

20 mg (Label)

Label for Lenalidomide Capsules 20 mg by Novugen Pharma (USA) LLC. The label includes a warning about potential human birth defects, storage instructions, and dosing advisory. It shows the package contains 21 capsules and indicates the product is made in India. The label features barcodes and a placeholder for a 2D data matrix with batch and serial number information.*

FDA Label Image

25 mg (Label)

Label for Lenalidomide Capsules, 25 mg strength, oral capsule form. The label includes a warning about potential human birth defects and storage instructions at 20°C to 25°C. Distributed by Novugen Pharma (USA) LLC, Princeton, NJ. The package contains 21 capsules and is marked Rx only. The label also states "Made in India" and features barcodes and a designated unvarnished area for batch details and serialization.*

FDA Label Image

5 mg (Label)

Label for Lenalidomide Capsules 5 mg from Novugen Pharma (USA) LLC, containing 28 capsules. The label includes storage instructions, a warning for potential human birth defects, and indicates the product is made in India. It also features NDC 82293-007-10, barcode, and manufacturer address in Princeton, NJ.*

FDA Label Image

Figure 1 (Figure1)

A Kaplan-Meier curve chart depicting Progression Free Survival (PFS) probability in percentage over time in months for three treatment groups: Rd Continuous, Rd 18, and MPT. The chart includes hazard ratios (HR), 95% confidence intervals (CI), and a logrank p-value for comparisons between groups. A table below shows the number of subjects at risk and PFS events for each group.*

FDA Label Image

Figure 2 (Figure2)

A survival probability Kaplan-Meier curve chart comparing overall survival over 72 months among three treatment groups: Rd Continuous, Rd 18, and MPT. The chart includes survival probability on the Y-axis and overall survival time in months on the X-axis, with a table below showing the number of subjects at risk at various time points and hazard ratios with confidence intervals for pairwise comparisons of the treatments.*

FDA Label Image

Figure 3 (Figure3)

A Kaplan-Meier curve chart showing progression-free survival over time in months for Lenalidomide versus placebo. The chart includes survival probability on the y-axis and time on the x-axis, with separate lines representing Lenalidomide and placebo groups. The number of subjects at risk at various time points is displayed below the x-axis.*

FDA Label Image

Figure 4 (Figure4)

A Kaplan-Meier curve graph depicting progression-free survival (months) comparing Lenalidomide and Placebo. The y-axis shows survival probability from 0 to 1, and the x-axis ranges from 0 to 108 months. Two survival curves are present: a solid line for Lenalidomide and a dashed line for Placebo. Below the graph is a table showing the number of subjects at risk over time for each group, along with PFS event counts and percentages for Lenalidomide and Placebo groups.*

FDA Label Image

Figure 5 (Figure5)

A Kaplan-Meier survival curve chart showing the proportion of subjects over time to progression in months. The chart compares two treatments: Lenalidomide/Dex and Placebo/Dex, illustrating a higher proportion of subjects without progression over time in the Lenalidomide/Dex group versus Placebo/Dex.*

FDA Label Image

Figure 6 (Figure6)

A Kaplan-Meier survival curve chart showing the proportion of subjects over time to progression in months for two treatment groups: Lenalidomide/Dex and Placebo/Dex. The graph includes a hazard ratio (HR) with 95% confidence interval and a significance level (p-value), illustrating differences between the two groups in disease progression over time.*

FDA Label Image

Figure 7 (Figure7)

A Kaplan-Meier survival curve chart showing progression-free survival probability over 48 months. It compares two groups: Rituximab plus Lenalidomide (solid line) and Rituximab plus Placebo (dashed line). The chart includes survival probability on the y-axis and time in months on the x-axis, with numbers of subjects at risk listed below the timeline.*

FDA Label Image

Chemical Structure (Structure01)

Chemical structure of the active ingredient Lenalidomide, depicted as a molecular diagram showing its ring and functional groups arrangement.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.